Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening lung disease with a global incidence of 0.09–1.30 per 10,000 individuals. Pirfenidone and nintedanib are the approved treatments for IPF. Objectives: This study evaluated the real-world safety and tolerabilit...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Therapeutic Advances in Drug Safety |
| Online Access: | https://doi.org/10.1177/20420986251341645 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717645308329984 |
|---|---|
| author | Alessio Provenzani Daniele Leonardi Vinci Miriam Alaimo Salvatore Di Maria Fabio Tuzzolino Gaetano Floridia Roberta Di Stefano Anna Carollo Adriana Callari Piera Polidori Patrizio Vitulo |
| author_facet | Alessio Provenzani Daniele Leonardi Vinci Miriam Alaimo Salvatore Di Maria Fabio Tuzzolino Gaetano Floridia Roberta Di Stefano Anna Carollo Adriana Callari Piera Polidori Patrizio Vitulo |
| author_sort | Alessio Provenzani |
| collection | DOAJ |
| description | Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening lung disease with a global incidence of 0.09–1.30 per 10,000 individuals. Pirfenidone and nintedanib are the approved treatments for IPF. Objectives: This study evaluated the real-world safety and tolerability profiles of pirfenidone and nintedanib in IPF patients treated at the Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT). A comparative analysis was conducted based on the number, types, and severity of adverse drug reactions (ADRs) and to identify potential predictors of treatment discontinuation or ADR onset based on patient characteristics. Design: A retrospective observational study was conducted on 531 IPF patients treated at IRCCS ISMETT with either pirfenidone or nintedanib. Methods: Eligible patients were selected based on the logged monthly dispensations provided by the pharmacy service for both therapies. Covariates were extracted from electronic medical records (age, sex, body mass index, smoking history, comorbidities, forced vital capacity (FVC) %, diffusing capacity of the lung for carbon monoxide (DLCO) %, 6-minute walk test (6-MWT), polytherapy, oxygen therapy, drug switch, etc.). ADRs were categorized by severity and follow-up status, and further classified according to the Medical Dictionary for Regulatory Activities, specifying the Preferred Terms and the related System Organ Classes. Chi-square or Fisher’s exact test was used for categorical variables, and univariate and multiple logistic regression identified potential risk factors for ADR onset. Backward Stepwise logistic regression (BSLR) was used to determine independent variables associated with ADR occurrence. Results: The nintedanib group had more frequent ADRs related to gastrointestinal and hepatobiliary disorders, with nausea, diarrhea, anorexia, and weight loss as the most common. The pirfenidone group had more ADRs related to skin, nervous system, and vascular disorders, such as rash, nausea, dizziness, and blood pressure imbalances. Significant baseline differences between groups included age, smoking status, FVC (%), DLCO (%), and 6-MWT, with the nintedanib cohort showing worse baseline characteristics. A total of 450 ADRs were reported: 59.6% for nintedanib and 40.4% for pirfenidone. Independent variables that significantly increased the likelihood of experiencing ADR were drug change, treatment type, gender, and age. Conclusion: Identifying ADR predictors is essential for personalizing treatment strategies. Both pirfenidone and nintedanib are crucial in managing IPF, highlighting the need for further research to optimize personalized therapies and patient outcomes. |
| format | Article |
| id | doaj-art-b8cb24f7e94147b594ee0f2d1f061b65 |
| institution | DOAJ |
| issn | 2042-0994 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Drug Safety |
| spelling | doaj-art-b8cb24f7e94147b594ee0f2d1f061b652025-08-20T03:12:35ZengSAGE PublishingTherapeutic Advances in Drug Safety2042-09942025-05-011610.1177/20420986251341645Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanibAlessio ProvenzaniDaniele Leonardi VinciMiriam AlaimoSalvatore Di MariaFabio TuzzolinoGaetano FloridiaRoberta Di StefanoAnna CarolloAdriana CallariPiera PolidoriPatrizio VituloBackground: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening lung disease with a global incidence of 0.09–1.30 per 10,000 individuals. Pirfenidone and nintedanib are the approved treatments for IPF. Objectives: This study evaluated the real-world safety and tolerability profiles of pirfenidone and nintedanib in IPF patients treated at the Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS ISMETT). A comparative analysis was conducted based on the number, types, and severity of adverse drug reactions (ADRs) and to identify potential predictors of treatment discontinuation or ADR onset based on patient characteristics. Design: A retrospective observational study was conducted on 531 IPF patients treated at IRCCS ISMETT with either pirfenidone or nintedanib. Methods: Eligible patients were selected based on the logged monthly dispensations provided by the pharmacy service for both therapies. Covariates were extracted from electronic medical records (age, sex, body mass index, smoking history, comorbidities, forced vital capacity (FVC) %, diffusing capacity of the lung for carbon monoxide (DLCO) %, 6-minute walk test (6-MWT), polytherapy, oxygen therapy, drug switch, etc.). ADRs were categorized by severity and follow-up status, and further classified according to the Medical Dictionary for Regulatory Activities, specifying the Preferred Terms and the related System Organ Classes. Chi-square or Fisher’s exact test was used for categorical variables, and univariate and multiple logistic regression identified potential risk factors for ADR onset. Backward Stepwise logistic regression (BSLR) was used to determine independent variables associated with ADR occurrence. Results: The nintedanib group had more frequent ADRs related to gastrointestinal and hepatobiliary disorders, with nausea, diarrhea, anorexia, and weight loss as the most common. The pirfenidone group had more ADRs related to skin, nervous system, and vascular disorders, such as rash, nausea, dizziness, and blood pressure imbalances. Significant baseline differences between groups included age, smoking status, FVC (%), DLCO (%), and 6-MWT, with the nintedanib cohort showing worse baseline characteristics. A total of 450 ADRs were reported: 59.6% for nintedanib and 40.4% for pirfenidone. Independent variables that significantly increased the likelihood of experiencing ADR were drug change, treatment type, gender, and age. Conclusion: Identifying ADR predictors is essential for personalizing treatment strategies. Both pirfenidone and nintedanib are crucial in managing IPF, highlighting the need for further research to optimize personalized therapies and patient outcomes.https://doi.org/10.1177/20420986251341645 |
| spellingShingle | Alessio Provenzani Daniele Leonardi Vinci Miriam Alaimo Salvatore Di Maria Fabio Tuzzolino Gaetano Floridia Roberta Di Stefano Anna Carollo Adriana Callari Piera Polidori Patrizio Vitulo Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib Therapeutic Advances in Drug Safety |
| title | Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib |
| title_full | Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib |
| title_fullStr | Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib |
| title_full_unstemmed | Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib |
| title_short | Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib |
| title_sort | real world insights into safety tolerability and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib |
| url | https://doi.org/10.1177/20420986251341645 |
| work_keys_str_mv | AT alessioprovenzani realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT danieleleonardivinci realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT miriamalaimo realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT salvatoredimaria realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT fabiotuzzolino realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT gaetanofloridia realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT robertadistefano realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT annacarollo realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT adrianacallari realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT pierapolidori realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib AT patriziovitulo realworldinsightsintosafetytolerabilityandpredictivefactorsofadversedrugreactionsintreatingidiopathicpulmonaryfibrosiswithpirfenidoneandnintedanib |